Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage

Recently, immune checkpoint inhibitors (iCIs) have been used to treat cancers. Once some of the iCIs for the treatment of hepatocellular carcinoma (HCC) are certified in clinical trials, they are likely be administered to HCC patients with hepatitis C virus (HCV). However, the immunopathogenesis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Ryo, Sugawara, Shunichi, Kondo, Yasuteru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578607/
https://www.ncbi.nlm.nih.gov/pubmed/32522918
http://dx.doi.org/10.2169/internalmedicine.3726-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578607/
https://www.ncbi.nlm.nih.gov/pubmed/32522918
http://dx.doi.org/10.2169/internalmedicine.3726-19

Ejemplares similares